Boston Scientific Corp (BSX)
Solvency ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.82 | 1.80 | 1.84 | 1.84 | 1.85 | 1.81 | 1.87 | 1.93 | 1.94 | 1.94 | 1.96 | 1.97 | 2.01 | 1.98 | 1.97 | 2.18 | 2.20 | 2.76 | 2.58 | 2.58 |
Solvency ratios provide insight into a company's ability to meet its long-term debt obligations. In the case of Boston Scientific Corp., the trends in key solvency ratios over the past eight quarters indicate a relatively stable financial position in terms of debt management.
The debt-to-assets ratio, measuring the proportion of assets financed by debt, remained relatively consistent around 0.26 to 0.29 over the period. This indicates that Boston Scientific has maintained a manageable level of debt in relation to its total assets.
The debt-to-capital ratio, which assesses the extent of debt used to finance the company's operations, also showed stability in the range of 0.32 to 0.36. This suggests that the company relies on a moderate level of debt in its capital structure.
The debt-to-equity ratio, reflecting the amount of debt relative to shareholders' equity, fluctuated between 0.47 and 0.56. While there was some variability, the ratio generally remained below 1, indicating that Boston Scientific relies more on equity financing than debt.
The financial leverage ratio, indicating the company's reliance on debt to finance its assets, ranged from 1.80 to 1.93. This suggests that Boston Scientific has maintained a relatively consistent level of leverage in its capital structure.
Overall, the solvency ratios of Boston Scientific Corp. suggest a balanced approach to debt management, with a reasonable level of leverage that has remained relatively stable over the past eight quarters. This indicates a solid financial position in terms of meeting long-term debt obligations.
Coverage ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | 8.81 | 8.15 | 6.97 | 6.78 | 3.51 | 2.89 | 2.82 | 2.41 | 3.52 | 3.05 | 1.36 | 0.41 | -0.22 | 0.18 | 1.47 | 2.49 | 3.22 | 4.56 | 5.10 | 5.69 |
Boston Scientific Corp.'s interest coverage has shown a positive trend over the past four quarters, increasing from 4.42 in Q4 2022 to 9.95 in Q4 2023. This indicates the company's ability to meet its interest obligations with its operating income has significantly improved. The interest coverage ratio, which measures the company's ability to cover its interest expenses with its operating income, demonstrates that Boston Scientific Corp. had more than enough operating income to cover its interest expenses in each quarter.
The consistent increase in the interest coverage ratio suggests that Boston Scientific Corp. has been effectively managing its debt and generating sufficient operating income to cover its interest payments. A ratio above 1 indicates a company is capable of meeting its interest obligations, with higher values signaling a stronger ability to do so.
Overall, the improving trend in Boston Scientific Corp.'s interest coverage ratio reflects a healthier financial position and enhanced financial stability.